GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, […]
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract
GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated
GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies
GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that an external committee of
GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed
